The American Journal of Managed Care12d
Nivolumab Approved as Neoadjuvant, Adjuvant Therapy for NSCLC by FDA
1 Patients were randomized 1:1 to neoadjuvant nivolumab plus platinum-doublet chemotherapy—from among carboplatin, cisplatin, paclitaxel, pemetrexed, and docetaxel 3 —surgery, and adjuvant ...
Business Insider28d
Purple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24
CM24+nivolumab+Nal-IRI/5FU/LV treatment of PDAC ... add supporting evidence for NETs as a new mechanism of action (MoA) and potential biomarker for CM24-based therapy,” said Dr. Hadas Reuveni ...
Medscape13d
Nivolumab NSCLC Approval Expanded to Perioperative Setting
The US Food and Drug Administration (FDA) has expanded the approval of nivolumab (Opdivo, Bristol Myers Squibb) for the treatment of certain patients with resectable non–small cell lung cancer ...
MedPage Today28d
Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer
In fact, median progression-free survival (PFS) decreased from 20.2 months with rucaparib (Rubraca) monotherapy to 15.0 months with the addition of nivolumab (Opdivo), translating into a hazard ...